Labcorp’s Post

What’s on the horizon for clinical trial technology? 🔍 Norwest Principal Brian Matesic, MD joined Sunny Kumar, Andrew Hedin, Carrie (Hurwitz) Williams, and Rana Lonnen on stage at #SCOPEsummit in Orlando to discuss an intriguing opportunity: the increasing complexity of clinical trials is creating space for start-ups to challenge—and even eclipse—traditional contract research organizations (CROs).    Key takeaways from their discussion:    🔄 Adaptability Is Key: To stay competitive, clinical trial tech startups need to stay nimble and align closely with pharma/biotech companies’ evolving needs.   📈 M&A on the Rebound: With interest rates poised to dip, they anticipate a resurgence in merger and acquisition activity, targeting complementary services and robust growth profiles across regions.   📱 The Digital Biomarker Revolution: The proliferation of advanced devices is ushering in a new era of more hybrid trials with novel, real-time endpoints.   🌟 Quality Over Size: High-quality execution in every trial is vital, setting the bar for future success and growth. Read a recap of the session here: https://lnkd.in/gCiFFZTv

Recession-linked downturn continues to be the major challenge biotech to remain competitive. Access to top talents and efficiency in drug development are key drivers to cope with the dire funding situation. In particular single-asset companies are often confronted with the dilemma of needing highly experienced experts for specific asks and tasks rather than continuously. Since now more than 10 years 2 Bridge embarks with founders, TTO and investors to create new ventures or accelerate assets via its unique Tiger Teams. By providing flexible, R&D experts, Tiger Teams address the needs along the drug product development process. The two recent examples of Kynexis and AbolerIS Pharma illustrate the power of Tiger Teams in leap frogging clinical translation. Check out our latest article for an in-depth look at the industry-changing strategies we're employing with Tiger Teams at 2 Bridge: How tiger teams are transforming the life sciences startup landscape https://lnkd.in/ef_DBWeP

2023 US seed-stage funding data reveals a challenge for medical device startups: low median cash from investors. This is a hurdle that is impeding both survival and speed toward market entry.   💡 Reach out to us at Eliomedica Inc, where we blend regulatory, scientific, and commercialization expertise to accelerate your market entry.   www.eliomedica.com   Thanks Daniel Kristensen and Sushee Perumal for sharing this.   #medicaldevice #regulatorystrategy #samd #medicalsoftware #marketentry #fdaregulations #digitalhealth #seedfunding

💻 Explore the latest post on biopharma unicorns set for IPOs in 2024! 🦄 #BiopharmaInnovation #IPO2024 #HealthcareFinance 📈 The biopharma sector is experiencing remarkable growth, with several companies gearing up for potential IPOs in 2024. This trend reflects the industry's commitment to innovation and the development of life-changing treatments. 📉 🔬 Technological advancements play a crucial role in driving these biopharma unicorns towards success. By harnessing cutting-edge tools and methodologies, these companies are revolutionizing healthcare and paving the way for future breakthroughs. 👩🏽💻 Embracing diversity in tech is essential for fostering creativity and driving inclusive innovation in the biopharma sector. By encouraging diverse perspectives and talents, companies can unlock new opportunities and enhance their competitive edge. 📍 Learn more about the biopharma unicorns poised for IPOs in 2024 and how NextRound.ai can support founders in navigating the fundraising landscape effectively. 💰💻✅ Visit a href="https://nextround.ai/blog/"NextRound.ai's blog post/a for valuable insights and resources on securing investments for your biopharma venture. #NextRound #BiopharmaFunding #FutureGrowth ☝🏽

🤔 What's more effective for #digitalhealth #startup business development than the #JPM2024 #healthcare conference? The PharmStars #accelerator!!   Digital health startups seeking #pharma clients can gain unparalleled access to pharma #digital #innovations decision-makers through the PharmStars #acceleratorprogram.   Startups learn the ins and outs of pharma during our #PharmaU program. They also get to attend private "Fireside Chats" with digital health champions from each of our pharma members, participate in a full day of presentations to and networking with pharma, and then sit down to 2 days of one-on-one meetings with pharma digital health leaders business and subject matter experts.   Go beyond #JPMorgan and do something really impactful for your business development pipeline: apply to participate in the next virtual PharmStars cohort before it is too late. Startups with a focus on "digital innovations in oncology" will be given priority. Deadline: February 1, 2024 Details and applications at: www.PharmStars.com #JPMWeek Meredith Cohen, Shwen Gwee, #noFOMO #Networking #businesspipeline #biotech #biopharma #partnerships #newclients

When startups and preclinical companies face the steep climb of tight budgets, limited resources, and the hunt for specialized talent, Compass steps in to catalyze growth. From establishing a U.S. presence for a Chinese biotech firm within budget to sourcing CRISPR experts in stealth-mode, our approach is strategic and effective. Check out these stories and more in our case study: https://lnkd.in/eYN-ndtD #LifeSciencesStaffing #LifeSciencesRecruiting #HiringSuccess #Preclinical #BiotechStartup

𝘽𝙞𝙤𝙩𝙚𝙘𝙝 𝙄𝙋𝙊𝙨 𝙎𝙡𝙤𝙬 𝘿𝙤𝙬𝙣, 𝘽𝙪𝙩 𝙋𝙧𝙚-𝙄𝙋𝙊 𝙁𝙞𝙣𝙖𝙣𝙘𝙞𝙣𝙜 𝙃𝙚𝙖𝙩𝙨 𝙐𝙥: 𝙄𝙨 𝙏𝙝𝙞𝙨 𝙖 𝙉𝙚𝙬 𝙏𝙧𝙚𝙣𝙙? The usual trajectory for promising biotech companies involved hitting the public markets after a couple of funding rounds. With the recent slowdown in IPO activity, we're seeing a shift. 𝗖𝗮𝘀𝗲 𝗶𝗻 𝗽𝗼𝗶𝗻𝘁: CG Oncology, the biotech who IPO’d this year, closed a massive $105 million Series F round just 5 months before going public, highlighting a growing trend of 𝐥𝐚𝐭𝐞-𝐬𝐭𝐚𝐠𝐞 𝐩𝐫𝐢𝐯𝐚𝐭𝐞 𝐟𝐢𝐧𝐚𝐧𝐜𝐢𝐧𝐠 in the biotech industry. Companies like FogPharma are staying private longer, even with eventual public market aspirations. They just secured Series E funding, including notable crossover investors like RA Capital, Fidelity, and Cormorant Asset Management, known for backing both public and private companies. 𝙒𝙝𝙖𝙩'𝙨 𝙙𝙧𝙞𝙫𝙞𝙣𝙜 𝙩𝙝𝙞𝙨 𝙩𝙧𝙚𝙣𝙙? Several factors are at play: 𝐒𝐥𝐨𝐰𝐞𝐫 𝐈𝐏𝐎 𝐦𝐚𝐫𝐤𝐞𝐭: With a less forgiving public market environment, companies are seeking alternative funding sources to advance their pipelines. 𝐈𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐝 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫 𝐢𝐧𝐭𝐞𝐫𝐞𝐬𝐭 𝐢𝐧 𝐩𝐫𝐞-𝐈𝐏𝐎 𝐬𝐩𝐚𝐜𝐞: As evidenced by FogPharma's round, seasoned investors are increasingly comfortable backing companies closer to commercialization, potentially offering higher return on investment. 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐚𝐝𝐯𝐚𝐧𝐭𝐚𝐠𝐞𝐬 𝐨𝐟 𝐬𝐭𝐚𝐲𝐢𝐧𝐠 𝐩𝐫𝐢𝐯𝐚𝐭𝐞: Staying private allows companies more flexibility in decision-making and avoids the short-term pressures often associated with public markets. The question remains: Will late-stage private financing become the new norm for the biotech industry?  #biotech #ipo #investing #privateequity

🌐 Internationalization: The Future of Biotech 🌐 Biotech startups face the crucial decision of starting as domestic companies, reliant on local resources, or embracing a born-global approach. The paper from https://lnkd.in/etawPwWA advocates for the latter, as I do, as born-global biotechs are better equipped to handle major industry challenges, especially during these tough times. Born-global biotechs actively pursue international market opportunities, providing extensive innovative scientific networks, ample capital, and diverse talent pools. Advantages of Born-Global Biotechs: 🌍 Access to World-Leading Science and Technology Platforms through Open Innovation 🌍 Wide Coverage of Global Markets to Address Local Unmet Needs 🌍 Maximized Opportunities to Leverage International Social Capital for Funding and Partnerships 🌍 Diverse Talent Pools with Unique Expertise and Training from Different Countries 🌍 Enhanced Operational Efficiency through Effective Resource Sharing across Global Sites Open Innovation: Born-global biotechs foster open innovation by building global networks, accessing cutting-edge science and technology beyond borders. This enables collaborative synergies with academic institutions and pharmaceutical companies for better discoveries. Social Capital: Global biotechs build social capital through partnerships with institutions and hospitals worldwide. This facilitates international funding and access to diverse patient populations for clinical trials, lowering costs and speeding up recruitment. Organizational Diversity: A global presence provides access to international talent pools, leading to diverse management teams that boost creativity and innovation, resulting in higher IPO raises. Challenges of Going Global: 🌍 Comprehensive Knowledge of International Regulation and Business Practices 🌍 Complexity of Ensuring Effective Internal Communication and Collaborations 🌍 Maintaining Local Uniqueness while Aligning with Global Cultural Values My experience in Global Operations has given me the opportunity to understand these advantages and overcome these challenges and I can provide guidance on the right path to global operations. By embracing a born-global strategy, biotech startups can overcome industry challenges, access diverse resources, and thrive in a highly competitive landscape. The benefits of open innovation, social capital, and organizational growth, when integrated efficiently, position born-global biotechs for sustained global success in the biotech industry. #InternationalOperations #GlobalSuccess #GlobalStrategy #AskAnExpert

🌟 Attention all Regulatory Affairs Experts in the MedTech realm! Have you ever considered leveraging your knowledge for the greater good of the community? Now's your moment! We've conducted a survey among regulatory affairs professionals, asking if they'd be willing to contribute 5 to 10 hours of pro bono consultations to assist emerging medtech startups. The response? An astounding 61% said they're on board! Introducing the Regulatory Rockstar Advisors Program – an exceptional opportunity tailored for experienced professionals like yourself to mentor the upcoming wave of MedTech pioneers. As a Regulatory Rockstar Advisor, you'll guide early-stage MedTech companies through the maze of regulatory strategies and compliance requirements. Don't miss out on this incredible chance to make a difference. Join the Regulatory Rockstar Movement at https://hubs.ly/Q02w38ns0 to gain access to this exclusive program. #ArazyGroup #Regulatory_Rockstar #RegulatoryAffairs #MedTech #RegTech #RegTechAI

🌟 Attention all Regulatory Affairs Experts in the MedTech realm! Have you ever considered leveraging your knowledge for the greater good of the community? Now's your moment! We've conducted a survey among regulatory affairs professionals, asking if they'd be willing to contribute 5 to 10 hours of pro bono consultations to assist emerging medtech startups. The response? An astounding 61% said they're on board! Introducing the Regulatory Rockstar Advisors Program – an exceptional opportunity tailored for experienced professionals like yourself to mentor the upcoming wave of MedTech pioneers. As a Regulatory Rockstar Advisor, you'll guide early-stage MedTech companies through the maze of regulatory strategies and compliance requirements. Don't miss out on this incredible chance to make a difference. Join the Regulatory Rockstar Movement at https://hubs.ly/Q02w39P30 to gain access to this exclusive program. #ArazyGroup #Regulatory_Rockstar #RegulatoryAffairs #MedTech #RegTech #RegTechAI